Shareholders Loan Agreement Sec

We look forward to the new alliance, the potential benefits it brings to Urovant and the future of our company,” said Keith Katkin, Urovant`s Ceo. As we prepare to submit our new application for Vibegron, access to Sumitomo Dainippon Pharmas` deep business know-how and ongoing financial commitment will help us ensure an effective deployment of Vibegron if the FFDA allows it. In addition, the sumitomo Dainippon Pharmas shareholder rights pact is a benchmark with many of our investors and shows their commitment and commitment to the urovant construction of a leading urology company. 1. We refer to the agreement (modified, different, new or completed from time to time) dated [mm dd, yyyy] and made between us as borrowers and them as lenders (loan contract). A shareholder loan contract, sometimes referred to as a shareholder credit contract, is an agreement between a shareholder and a company that describes the terms of a loan (such as the repayment plan and interest rates) when a company lends money to a shareholder or owes money to a shareholder. Debt (excluding prepaid interest) provided by a Lien on the property or acquired by that person (including debt resulting from conditional sales or other property reserve contracts), regardless of whether that debt was taken over by that person or is limited to recourse; Sumitomo`s loan agreement means that a specific loan agreement, dated to the date of this agreement, between Sumitomo and the company under which Sumitomo agreed to provide the company with a $200 million long-term loan facility, subject to the terms of the loan agreement. Section 2.2 Company registration. If the Company proposes to register any of its common shares under the Securities Act as part of the public offering of these securities exclusively for cash payment (except in an excluded registration) (including a registration made by the Company for shareholders other than the holders), it will immediately notify each holder of that registration on that date. At the request of any licensee given within 20 days of the company`s filing, the company will occur, subject to the second form of Redaction, if the SEC responds to a company`s request to withhold certain information from its loan agreements with the Agency, the study said. Nevertheless, Saavedra found that 73% of loan contracts were published in its sample, “less than 1% of debt contracts provide that the SEC accepted the borrower`s request not to disclose information,” the study says. In other words, it appears that information is often withheld without express SEC authorization.

“We welcome the long-term loan facility and additional flexibility offered by urovant as we prepare to submit our new drug application for Vibegron, which has the potential to be a first-class prescription treatment for patients with an overactive bladder,” said Keith Katkin, Chief Executive Officer of Urovant. Sumitomo Dainippon Pharmas` desire to increase the facility by $100 million of the $200 million initially agreed demonstrates its faith in Vibegron and its long-term commitment to Urovant. This $300 million loan facility is available by Urovant in capital until 2021, so no short-term equity financing is required. (b) The company presents to the previous licensee a certificate signed by the company`s chief executive that, on the principle of the board of directors, the company and its shareholders would be seriously penalizing if such a registration statement becomes effective or remains effective, to the extent that such registration statement would be necessary to remain effective. Since such a measure (i) would significantly affect a major acquisition, corporate restructuring or similar transaction in which the company is involved; (ii) require the early disclosure of essential information that the company must treat as confidential; or (iii) the company

Dieser Beitrag wurde unter Allgemein veröffentlicht. Setze ein Lesezeichen auf den Permalink.